AstraZeneca Plc will sell commercial rights for two products to a German pharmaceutical company for $400 million as the British drugmaker looks to focus on newer medicines in new therapy areas.
The European medicines watchdog recommended approving AstraZeneca’s treatments for a form of heart failure and a lung disorder, the British drugmaker said.
Cytokinetics’ stocks plummeted after the company released topline results from a Phase III cardiovascular clinical trial with partners Amgen and Servier in which the secondary endpoint to prove potential to save lives failed.
Boehringer Ingelheim and Eli Lilly announced that the EMPEROR-Reduced Phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes, met the primary endpoint.
Novartis’ Sandoz division will not profit from 15 generic drugs the company is making available to developing countries to treat symptoms of Covid-19 for the pandemic’s duration, the Swiss drugmaker said.
The U.S. Food and Drug Administration approved Farxiga (dapagliflozin) for the treatment of heart failure in adults with reduced ejection fraction.
New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trial showed that AstraZeneca’s Farxiga (dapagliflozin) reduced the incidence of the primary composite endpoint of heart failure worsening or cardiovascular death compared to placebo, in patients with heart failure with reduced ejection fraction, irrespective of their background therapy.
Three months after winning FDA approval in type 2 diabetes, AstraZeneca is eyeing a potential U.S. regulatory win for Farxiga as a treatment in heart failure patients.
Merck & Co. Inc.’s experimental treatment vericiguat being developed with Bayer AG for patients with worsening chronic heart failure met the main goal of a late-stage study.
AstraZeneca announced new data from five additional analyses of the landmark Phase III DAPA-HF trial, which showed that Farxiga (dapagliflozin) reduced the risk of the primary composite outcome of worsening heart failure or death from cardiovascular causes versus placebo, when added to standard of care.